LYEL Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. (LYEL) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $149.0K.
Where they traded
Last open-market purchase: March 6, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Shook David | Chief Medical Officer | Sell | 500 | $12.70 | $6.4K | 20,423 −2.4% of holding | |
| Seely Lynn | President and CEO | Sell | 9,589 | $15.54 | $149.0K | 63,899 −13% of holding | |
| Lee Gary K. | Chief Scientific Officer | Sell | 1,457 | $15.54 | $22.6K | 16,220 −8.2% of holding | |
| Hill Stephen J. | Chief Operating Officer | Sell | 989 | $15.54 | $15.4K | 16,816 −5.6% of holding | |
| Bulis Veronica Sanchez | VP, Corporate Controller | Sell | 621 | $14.34 | $8.9K | 14,799 −4% of holding | |
| Seely Lynn | President and CEO | Sell | 390 | $14.34 | $5.6K | 73,488 −0.5% of holding | |
| Lee Gary K. | Chief Scientific Officer | Sell | 131 | $14.34 | $1.9K | 17,677 −0.7% of holding | |
| Hill Stephen J. | Chief Operating Officer | Sell | 89 | $14.34 | $1.3K | 17,805 −0.5% of holding | |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sell | 10 | $13.70 | $137 | 2,857,480 −0% of holding | |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | Sell | 10 | $13.73 | $137 | 2,857,490 −0% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.